Sharekhan's research report on Zydus Wellness
Subdued demand, seasonal vagaries, and category-specific issues led to muted revenue growth in FY2024. However, ZWL maintained its leadership position in most categories it operates in. Strong summers led to a stellar performance in Q1FY2025. Cash flow generation stayed strong, with FCF at Rs. 218 crore (FCF/EBIDTA of 71%); Return ratios have bottomed out at ~5% and are expected to see improvement going ahead. We expect ZWL to deliver a revenue/PAT CAGR of 14%/34%, respectively over FY2024-FY2026E driven by distribution expansion, innovation, effective media and promotion and cost efficiencies.
Outlook
We maintain a Buy on Zydus Wellness Limited (ZWL) with an unchanged PT of Rs. 3,000. Stock has run up by 32% since our upgrade to Buy on May 14, 2024 and currently trades at 37x/29x its FY2025E/FY2026E EPS, respectively.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
